Plain-English translation of NCT06411600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The BRAVE trial is testing a combination of three medications—, , and —to treat advanced colorectal cancer in patients whose tumors have a specific genetic mutation called BRAF-V600E. This combination targets cancer cells in multiple ways at once. The study will measure how well this treatment works and how safe it is compared to standard care.
Patients with this specific genetic mutation in their colorectal cancer often don't respond well to standard chemotherapy alone. Researchers believe that combining three targeted drugs may work better by attacking the cancer from different angles and overcoming resistance to treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would take an oral pill called once daily and receive two intravenous infusions ( and ) every two weeks. Treatment continues in 28-day cycles as long as the cancer responds and you tolerate the medication well. You'll have regular blood tests, scans to measure your cancer, and check-ins with your doctor to monitor how you're responding and watch for side effects.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Spain